INIncyte INCY · NASDAQ
$113.07 -0.18% (-$0.20)
- Market cap
- $22.9B
- Enterprise value
- $19.0B
- P/E
- 14.2x
- Forward P/E
- 34.8x
- PEG
- 0.0x
- P/S
- 3.9x
- P/FCF
- 11.9x
- EV/EBITDA
- 9.3x
- ROIC
- 22.9%
- Bruto marža
- 92.6%
- Neto marža
- 27.7%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -1.9x
- Beta
- 0.74
- Free float
- 99.1%
O podjetju
Incyte Corporation (INCY) is an American biopharmaceutical company specializing in the research, development, and commercialization of therapies focused on oncology and other serious diseases. The company is known for its strong emphasis on scientific research and innovation, leading to the discovery of new therapeutic possibilities. Incyte focuses on developing small molecule drugs and immunotherapies that have the potential to significantly improve patients' lives. Incyte Corporation (INCY) shares might be appealing to investors seeking involvement in the biotechnology sector with a focus on innovation and treatment of serious diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
William J. Meury
Employees
2,844
Headquarters
Wilmington
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke